News and Trends 21 Sep 2022 Poolbeg to investigate melioidosis vaccine candidate Poolbeg Pharma has signed an exclusive agreement with University College Dublin (UCD) through NovaUCD, the university’s knowledge transfer office, for a late preclinical stage vaccine candidate for melioidosis, a disease for which there is no current approved vaccine available.The vaccine candidate, which is being developed by Poolbeg Pharma as POLB 003, was invented following many […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Emactuzumab designated as an orphan medicinal product for TGCT in Europe SynOx Therapeutics Limited says its novel monoclonal antibody, emactuzumab, in development for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been designated as an orphan medicinal product for both localized and diffuse types of the disease by the European Medicines Agency (EMA). No systemic treatments have been approved for TGCT in […] August 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Gene therapies for lung cancer identified by international team of scientists Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […] August 24, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Trinity, St. James’s and Legend Biotech collaborating on solid tumors Trinity College and St. James’s Hospital Dublin (SJH) in Ireland have entered into a strategic collaboration with Legend Biotech, a global biotechnology company developing, manufacturing and commercializing novel therapies. Together, they will develop 3D models exploring chimeric antigen receptor T-cell (CAR-T) cell therapies in solid tumors. CAR T-cell therapies are customized for each individual patient. […] June 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2021 Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain Last month’s EU approval of Vazkepa — a treatment derived from fish oil and branded as Vascepa in the US — has added much-needed ammunition to the arsenal of doctors battling cardiovascular disease. Yet other similar treatments are returning lukewarm results and the possibility of approvals being withdrawn hangs in the air. Icosapent ethyl, a […] April 21, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2019 Iterum Therapeutics Reels from Antibiotic Phase III Fail An antibiotic candidate developed by the Irish company Iterum Therapeutics has failed to meet the main goal of a phase III trial, a blow for efforts to meet the challenge of global antibiotic resistance. Iterum Therapeutics’ drug sulopenem was tested in a phase III trial that recruited 674 patients suffering from complicated intra-abdominal infections. These […] December 12, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2019 Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz Pharmaceutical’s experimental drug was able to reduce the number of cataplexy attacks and the […] September 26, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 23 May 2019 Irish Life Sciences VC Raises €118M Fund with European Focus Fountain Healthcare Partners has raised €118M in its third fund dedicated to investing in life sciences, with the majority of the funds destined to go to European companies. Of the total raised, €45M was contributed by the European Investment Fund, which invested in both of Fountain’s previous funds. Other investors are Coolidge Limited, the Ireland […] May 23, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2019 First Plant in the Works to Turn Dairy Byproducts Into Plastics The company Glanbia Ireland is planning to construct the first industrial biorefinery that transforms dairy waste products into lactic acid, a building block for biodegradable plastics. Supported by the EU project AgriChemWhey, Glanbia Ireland plans to scale up biorefinery technology that ferments dairy waste, like whey permeate, into lactic acid, using a group of bacteria […] February 13, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 19 Nov 2018 Anti-Inflammatory Treatments Get €40M Boost in Series B A Series B funding round has whipped up €40M for the Irish company Inflazome. This money will help to fund clinical trials for anti-inflammatory treatments targeting conditions such as Alzheimer’s and Parkinson’s disease. “We are extremely excited about this opportunity, which is such a large funding round in a European company,” Marco Boorsma, General Partner […] November 19, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2018 Parkinson’s Disease Vaccine Shows Preclinical Promise The biotech company United Neuroscience has developed a candidate Parkinson’s disease vaccine that targets a protein linked to the condition. The vaccine teaches the immune system to attack aggregations of alpha-synuclein. When this protein aggregates in neurons, it can lead to several neurodegenerative disorders, including Parkinson’s. In United Neuroscience’s preclinical study, the vaccine was able to prevent the […] November 14, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2018 Nestlé and AI Biotech Hunt Down Bioactive Peptides in Our Food Nuritas and Nestlé will use artificial intelligence to find bioactive peptides in the food we eat for applications including diabetes, anti-aging, and animal and plant health. Nuritas wants to revolutionize the discovery of natural active ingredients that can support and improve human health. The company uses artificial intelligence (AI) to look closely at the foods we […] February 14, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email